A method for synthesizing cinoramide

By improving the synthesis route of cinuoamine and using halogen-magnesium exchange and ruthenium chiral catalysts, the problems of low yield and high cost in the existing technology have been solved, and the production of cinuoamine with high selectivity and high purity has been achieved, which is suitable for industrial application.

CN123106565APending Publication Date: 2026-11-17CHONGQING SHENGHUAXI PHARMA CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611294960.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-08-25
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing synthetic routes for cinuoamine esters suffer from low yield, high cost, and difficulty in large-scale production. In particular, the poor selectivity between 1N ketones and 2N ketones leads to insufficient purity and economic efficiency.

Method used

A halogen-magnesium exchange reaction was carried out with 1,2-dichlorobenzene and isopropyl magnesium bromide, followed by N-alkylation-directed modification with tetrazolium, asymmetric reduction with a ruthenium chiral catalyst, and finally esterification with chlorosulfonic isocyanate. The reaction conditions were optimized to improve selectivity and yield.

Benefits of technology

It significantly improved the selectivity at the 2N site to over 95%, reduced byproducts, lowered production costs, and achieved high-yield production of high-purity cinnoamino ester, making it suitable for large-scale industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure QLYQS_1
    Figure QLYQS_1
  • Figure QLYQS_2
    Figure QLYQS_2
Patent Text Reader

Abstract

This invention discloses a method for synthesizing cinnoamino ester, belonging to the field of pharmaceutical synthesis technology. The method uses 1,2-dichlorobenzene as a starting material, which undergoes halo-magnesium exchange to obtain 2-chlorophenyl magnesium chloride (compound I); 2-tetrazazole acetonitrile (compound II) is obtained with high selectivity through an N-alkylation reaction of tetrazolium and bromoacetonitrile under alkaline conditions, exhibiting a 2N-position selectivity ≥95%; Compound I and Compound II are then subjected to Grignard addition to obtain a ketone intermediate (compound III); subsequently, asymmetric reduction with a ruthenium chiral catalyst yields a chiral alcohol (compound IV); finally, esterification with chlorosulfonic acid isocyanate yields cinnoamino ester. This invention features a short route, mild reaction conditions, inexpensive and readily available raw materials, significantly higher 2N-position isomer selectivity and overall yield than the original research route, and a final product purity ≥99% and ee ≥99%, making it suitable for large-scale industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of pharmaceutical technology, specifically a method for preparing cinnoamino ester. Background Technology

[0002] Epilepsy is one of the most common neurological disorders worldwide and is listed by the World Health Organization as one of the five most intractable neurological diseases. Statistics show that the prevalence of epilepsy in my country is approximately 7 per 1,000, with a total of about 10 million patients, of whom 6.4 million have active epilepsy. Approximately 300,000 new cases are diagnosed each year, and focal epilepsy accounts for as much as 60%. More seriously, about 30%-40% of patients do not respond well to existing antiepileptic drugs (ASMs), becoming drug-resistant epilepsy patients. Even with combination therapy of 1-3 drugs, these patients still struggle to effectively control seizures. For a long time, the rate of seizure-free status achieved through adjunctive therapy in patients with intractable epilepsy has remained below 10%, highlighting the urgent clinical need for more effective treatments.

[0003] Sinuolam, developed and marketed by SK Life Sciences, is a novel tetrazolium carbamate derivative that inhibits sustained sodium ion currents and possesses broad-spectrum anticonvulsant activity. It effectively suppresses epilepsy in focal epilepsy models and exerts its antiepileptic effect by modulating γ-aminobutyric acid (GABA) receptors to inhibit nerve impulses and reduce neuronal excitability. This drug was approved by the FDA in November 2019 and is considered an innovative treatment for epilepsy.

[0004] The structure of cinuo amino ester is as follows:

[0005] Chemical name: [(1R)-1-(2-chlorophenyl)-2-(tetrazole-2-yl)ethyl]carbamate Molecular formula: C 10 H 10 ClN5O2 Molecular weight: 267.67 CAS No.: 913088-80-9 There are two main methods for preparing cinnoamino ester, as reported in domestic and international literature and patents: Prior Art 1: The original research company SK Corporation's compound patent CN101228138 reports the following synthetic route: ; This route uses enzyme catalysis to obtain a chiral alcohol hydroxyl group from 2-bromo-2'-chloroacetophenone, followed by epoxidation and nucleophilic reaction with tetrazolium, and finally condensation with chlorosulfonic acid isocyanate to obtain the target product. This route has poor selectivity for epoxide ring opening, resulting in 1N ketone and 2N ketone structures, low overall yield, and difficulty in achieving large-scale production.

[0006] The structures of 1N ketones and 2N ketones are as follows: .

[0007] Prior Art 2: The synthetic route reported in patent CN102803233 of the original manufacturer SK Corporation is as follows: ; The route first reacts 2-bromo-2'-chloroacetophenone with tetrazolium, followed by asymmetric reduction to prepare a chiral alcohol, which is then further reacted to obtain cinnoacetate. In the first step, the tetrazolium reaction site has two selectivity points, resulting in the production of both 1N and 2N ketones, leading to a low yield. The second step in this patent uses either enzyme catalysis or a chiral reducing agent catalysis. Custom-developed enzymes are costly, while chiral catalysts offer certain advantages. Building on this, SK Corporation further applied for patent CN114901647A in 2020. This patent indicates that reacting 1H-tetrazole with an inorganic base to prepare a 1H-tetrazole metal salt, followed by the addition of 2-bromo-2'-chloroacetophenone, can improve the yield of 2N ketone, but there are still areas for improvement.

[0008] In summary, the synthetic methods in these patent documents have proposed new synthetic ideas and preparation methods from different perspectives. However, these routes still have certain shortcomings for large-scale production. Further research is needed on low-cost, high-efficiency, and high-yield green synthetic routes for sinoamine ester, which is crucial for the economic and technological development of sinoamine ester active pharmaceutical ingredient. Summary of the Invention

[0009] The purpose of this invention is to address the shortcomings of existing cinuo amino acid ester technology by providing a simple, high-yield, high-purity, and relatively economical method for large-scale industrial production.

[0010] This invention improves existing technology by changing the synthesis strategy, thereby increasing the selectivity of the 2N site reaction of tetrazolium to over 95%, greatly reducing the generation of byproducts, and then obtaining high-purity cinnoamino ester in high yield through chiral reduction. The invention provides the following technical solution.

[0011] This invention uses commercially available 1,2-dichlorobenzene as a starting material to prepare cinnoamino ester, and the route is as follows: .

[0012] Specifically, the following steps are included: The reaction formula for step 1 is as follows: ; Compound I was obtained by halogen-magnesium exchange reaction of 1,2-dichlorobenzene with isopropyl magnesium bromide. Specifically, under nitrogen protection, 1,2-dichlorobenzene was dissolved in dry solvent 1, and the solution of isopropyl magnesium bromide in solvent 1 was slowly added dropwise at low temperature. After the reaction was completed, the solvent 1 solution of compound I was obtained and directly used for subsequent reactions. In step 1, during the preparation of compound I, the molar ratio of 1,2-dichlorobenzene to isopropyl magnesium bromide is 1:1.1 to 1.4, preferably (1:1.1 to 1.2). In step 1, during the preparation of compound I, solvent 1 is selected from one or a mixture of several of tetrahydrofuran (THF), methyltetrahydrofuran (Me-THF), diethyl ether, and dichloromethane (DCM); In step 1, during the preparation of compound I, the low temperature conditions used are -10 to -40°C, preferably -10 to -20°C.

[0013] The reaction formula for step 2 is as follows: ; Starting with tetrazolium, a substitution reaction was carried out with bromoacetonitrile to obtain compound II. Specifically, tetrazolium was dissolved in solvent 2, base 1 was added, and bromoacetonitrile was slowly added dropwise. After the reaction was completed, compound II was obtained. In step 2, during the preparation of compound II, the molar ratio of tetrazolium to bromoacetonitrile used is 1:1.1 to 1.3, preferably (1:1.1 to 1.2). In step 2, during the preparation of compound II, solvent 2 is selected from one or a mixture of several of acetonitrile, N,N-dimethylformamide (DMF), N,N-methylacetamide (DMAC), and dimethyl sulfoxide (DMSO); In step 2, during the preparation of compound II, the base used is selected from one or a mixture of several of potassium carbonate, sodium carbonate, cesium carbonate, lithium hydroxide, and sodium hydride; In step 2, during the preparation of compound II, the molar ratio of tetrazolium to base used is 1:3 to 5, preferably (1:3 to 4).

[0014] The reaction formula for step 3 is as follows: ; Under nitrogen protection, compound I and compound II undergo an addition reaction to obtain compound III. Specifically, compound II is dissolved in a dry solvent, and a solution of compound I is slowly added. After the reaction is complete, compound III is obtained. In step 3, during the preparation of compound III, the molar ratio of compound II to compound I is 1:1 to 1.3, preferably (1:1 to 1.2). In step 3, during the preparation of compound II, solvent 3 is selected from one or a mixture of several of tetrahydrofuran (THF), methyltetrahydrofuran (Me-THF), diethyl ether, and dichloromethane (DCM).

[0015] The reaction formula for step 4 is as follows: ; Under nitrogen protection, compound III undergoes a chiral reduction reaction to obtain compound IV. Specifically, compound III is dissolved in a dry solvent, a chiral reducing agent is added, and after the reaction is complete, compound IV is obtained. In step 4, during the preparation of compound IV, the molar ratio of compound III to the chiral reducing agent is 1:0.003 to 0.007, preferably (1:0.004 to 0.005). In step 4, the chiral reducing agent used in the preparation of compound IV is {[(1S,2S)-(-)-2-amino-1,2-diphenylethyl](4-toluenesulfonyl)amino}(p-isopropyltoluene)ruthenium(II)); In step 4, during the preparation of compound IV, solvent 4 is a mixed solvent of formic acid and triethylamine (5:2) by volume. In step 4, during the preparation of compound IV, the mass-to-volume ratio of compound III to solvent 4 is 1:4 to 6, preferably (1:4 to 5).

[0016] The reaction formula for step 5 is as follows: ; Under nitrogen protection, compound IV undergoes an esterification reaction, specifically by dissolving compound IV in a dry solvent, adding chlorosulfonic acid isocyanate for esterification, and obtaining cinuo amino ester after the reaction is complete. In step 5, during the preparation of cinuo amino acid ester, the molar ratio of compound IV to chlorosulfonic acid isocyanate is 1:1.2 to 1.5, preferably (1:1.2 to 1.4). Step 5: In the preparation of cinuo amino ester, solvent 5 is selected from one or a mixture of several of tetrahydrofuran (THF), methyltetrahydrofuran (Me-THF), acetonitrile, and dichloromethane (DCM).

[0017] This invention provides a method for preparing cinnoamino ester, which has the following main advantages: This invention prepares compound II by obtaining compound I through a Grignard exchange reaction and compound II through a substitution reaction. Due to the different reaction substrates, bromoacetonitrile is used to perform N-alkylation directional modification on tetrazolium, achieving a 2N-position selectivity of ≥95%, significantly inhibiting the formation of byproducts at the 1N-position, eliminating the complex isomer separation steps, reducing purification losses and production costs, and showing a significant advantage compared to the original drug's approximately 50% selectivity.

[0018] The present invention provides a simple route for preparing cinnoamino ester, which involves halogen-magnesium exchange between 1,2-dichlorobenzene and isopropylmagnesium bromide. The reaction conditions are mild, requiring no high temperature or high pressure, resulting in fewer side reactions. Grignard reagent solution can be directly added, improving process continuity and atom economy. Using a ruthenium chiral catalyst, the asymmetric reduction of compound III can be achieved with a product ee value ≥99% at a dosage of only 0.3%~0.7%. Enzyme catalysis is not required, resulting in lower cost and better reproducibility.

[0019] In summary, this route uses inexpensive raw materials, has mild reaction conditions, and can produce cinnoamino esters in high yields, resulting in significant economic benefits and making it suitable for large-scale industrial production. Detailed Implementation

[0020] To further understand the present invention, the preparation method of the sinoamine ester provided by the present invention will be described in detail below with reference to the embodiments. It should be understood that these embodiments are described only to further illustrate the features of the present invention, and are not intended to limit the scope of the present invention or the scope of the claims of the present invention.

[0021] Example 1: 1) Preparation of compound I (2-chlorophenyl magnesium chloride) Under nitrogen protection, 150 g (1.02 mol) of 1,2-dichlorobenzene and 1200 mL of THF were added to a reaction flask and stirred to dissolve. The temperature was then lowered to -15 to -20 °C, and 1173 mL of isopropyl magnesium bromide solution (1 mol / L) was slowly added dropwise while maintaining the temperature ≤ -10 °C for approximately 1 hour. The reaction was maintained at this temperature with stirring for 3 hours. After the reaction was complete, a THF solution of compound I was obtained, which was sealed and stored under nitrogen atmosphere for direct use in the next step.

[0022] 2) Preparation of compound II (2-tetrazole acetonitrile) Under nitrogen protection, 100 g (1.428 mol) of tetrazolium, 691 g (5.0 mol) of anhydrous potassium carbonate, and 1400 mL of LDM were added to a reaction flask and stirred at room temperature for 30 min. 196.6 g (1.642 mol) of bromoacetonitrile was slowly added dropwise at 25–30 °C over approximately 1 h. The temperature was raised to 40 °C and the reaction was stirred for 5 h. After the reaction was complete, the mixture was cooled to room temperature, filtered to remove insoluble matter, and the filtrate was concentrated to dryness under reduced pressure. The filtrate was dissolved in 500 mL of ethyl acetate, washed successively with 200 mL of water and 200 mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give 148 g of compound II, with a yield of 95% and a purity of 96%.

[0023] 3) Preparation of compound III (2-chlorophenyl-2-tetrazolylethyl ketone) Under nitrogen protection, 100 g (0.735 mol) of compound II and 700 ml of THF were added to a reaction flask and stirred to dissolve. The mixture was cooled to 0–5 °C, and a THF solution of compound I (0.809 mol) was slowly added dropwise while maintaining the temperature ≤10 °C for approximately 1 hour. The mixture was then heated to 20–25 °C and stirred for 4 hours. After the reaction was complete, the mixture was cooled to 0 °C, and a saturated ammonium chloride solution was slowly added dropwise to quench the reaction, followed by stirring for 30 minutes. The mixture was extracted three times with 300 ml of ethyl acetate each time. The organic phases were combined and washed successively with 200 ml of water and 200 ml of saturated brine. The mixture was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and dried to obtain 194 g of compound III, with a yield of 95% and a purity of 98%.

[0024] 4) Preparation of compound IV ((R)-2-chlorophenyl-2-tetrazolylethyl alcohol) Under nitrogen protection, 100 g (0.376 mol) of compound III was added to a reaction flask, followed by 500 ml of formic acid-triethylamine (5:2). The mixture was stirred to dissolve the compound, and then 1.24 g (0.00188 mol) of chiral ruthenium catalyst was added. The mixture was stirred at 20–25 °C for 12–14 h. After the reaction was complete, 600 ml of ethyl acetate and 600 ml of saturated brine were added. The mixture was allowed to separate into two layers, yielding an ethyl acetate layer. The organic layer was washed twice with 300 ml of saturated brine each time. The organic layer was dried with anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and dried to obtain 96 g of compound IV. The yield was 95%, the purity was 99%, and the ee ≥ 99%.

[0025] 5) Preparation of sinoamino ester Under nitrogen protection, 100 g (0.374 mol) of compound IV and 1000 ml of tetrahydrofuran were added to a reaction flask and stirred to dissolve. The mixture was then cooled to -10 to -5 °C, and 68.8 g (0.486 mol) of chlorosulfonic acid isocyanate was slowly added dropwise over approximately 1 hour. The reaction was maintained at this temperature and stirred for 2 hours. After the reaction was complete, 200 ml of water was slowly added to quench the reaction, and the mixture was stirred for 30 minutes. The tetrahydrofuran was removed under reduced pressure. The residue was then added to 600 ml of ethyl acetate and washed three times with 200 ml of saturated brine each time. The ethyl acetate layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was then slurried with 100 ml of isopropanol and 500 ml of n-hexane for 30 minutes, filtered, and dried to obtain 112 g of cinnoamino ester, with a yield of 94% and a purity of 99%.

Claims

1. A method for preparing cinnoamino ester, comprising the following steps: 。 2. The preparation method according to claim 1, wherein the reaction formula in step 1 is as follows: ; Compound I was obtained by halogen-magnesium exchange reaction of 1,2-dichlorobenzene with isopropyl magnesium bromide. Specifically, under nitrogen protection, 1,2-dichlorobenzene was dissolved in dry solvent 1, and the solution of isopropyl magnesium bromide in solvent 1 was slowly added dropwise at low temperature. After the reaction was completed, the solvent 1 solution of compound I was obtained and directly used for subsequent reactions. wherein In step 1, during the preparation of compound I, the molar ratio of 1,2-dichlorobenzene to isopropyl magnesium bromide is 1:1.1 to 1.

2. In step 1, during the preparation of compound I, solvent 1 is selected from one or a mixture of several of tetrahydrofuran (THF), methyltetrahydrofuran (Me-THF), diethyl ether, and dichloromethane (DCM). In step 1, during the preparation of compound I, a low temperature condition of -10 to -20°C is used.

3. The preparation method according to claim 1, wherein the reaction formula in step 2 is as follows: ; Starting with tetrazolium, a substitution reaction was carried out with bromoacetonitrile to obtain compound II. Specifically, tetrazolium was dissolved in solvent 2, base 1 was added, and bromoacetonitrile was slowly added dropwise. After the reaction was completed, compound II was obtained. wherein In step 2, during the preparation of compound II, the molar ratio of tetrazolium to bromoacetonitrile used was 1:1.1 to 1.

2. In step 2, during the preparation of compound II, solvent 2 is selected from one or a mixture of several of acetonitrile, N,N-dimethylformamide (DMF), N,N-methylacetamide (DMAC), and dimethyl sulfoxide (DMSO). In step 2, during the preparation of compound II, the base used is selected from one or a mixture of several of potassium carbonate, sodium carbonate, cesium carbonate, lithium hydroxide, and sodium hydride. In step 2, during the preparation of compound II, the molar ratio of tetrazolium to base is 1:3 to 4.

4. The preparation method according to claim 1, wherein the reaction formula in step 3 is as follows: ; Under nitrogen protection, compound I and compound II undergo an addition reaction to obtain compound III. Specifically, compound II is dissolved in a dry solvent, and a solution of compound I is slowly added. After the reaction is complete, compound III is obtained. wherein In step 3, during the preparation of compound III, the molar ratio of compound II to compound I is 1:1 to 1.

2. In step 3, during the preparation of compound III, solvent 3 is selected from one or a mixture of several of tetrahydrofuran (THF), methyltetrahydrofuran (Me-THF), diethyl ether, and dichloromethane (DCM).

5. The preparation method according to claim 1, wherein the reaction formula in step 4 is as follows: ; Under nitrogen protection, compound III undergoes a chiral reduction reaction to obtain compound IV. Specifically, compound III is dissolved in a dry solvent, a chiral reducing agent is added, and after the reaction is complete, compound IV is obtained. wherein In step 4, during the preparation of compound IV, the molar ratio of compound III to the chiral reducing agent is 1:0.004 to 0.

005. In step 4, during the preparation of compound IV, the chiral reducing agent used is {[(1S,2S)-(-)-2-amino-1,2-diphenylethyl](4-toluenesulfonyl)amino}(p-isopropyltoluene)ruthenium(II)); In step 4, during the preparation of compound IV, solvent 4 is a mixed solvent of formic acid and triethylamine (5:2) in volume ratio; In step 4, during the preparation of compound IV, the mass-to-volume ratio of compound III to solvent 4 is 1:4 to 5.

6. The preparation method according to claim 1, wherein the reaction formula in step 5 is as follows: ; Under nitrogen protection, compound IV undergoes an esterification reaction, specifically by dissolving compound IV in a dry solvent, adding chlorosulfonic acid isocyanate for esterification, and obtaining cinuo amino ester after the reaction is complete. wherein, In step 5, during the preparation of cinuo amino acid ester, the molar ratio of compound IV to chlorosulfonic acid isocyanate is 1:1.2 to 1.

4. In step 5, during the preparation of cinuo amino ester, solvent 5 is selected from one or a mixture of several of tetrahydrofuran (THF), methyltetrahydrofuran (Me-THF), acetonitrile, and dichloromethane (DCM).